BI-847325 is primarily investigated for its potential in cancer therapy, particularly as an inhibitor of MEK and Aurora kinases, which are crucial in cell cycle regulation and tumor growth. By targeting these kinases, it aims to disrupt the proliferation of cancer cells and induce apoptosis. Its application is most relevant in preclinical studies for treating various cancers, including solid tumors and hematologic malignancies. Researchers are exploring its efficacy in combination with other anticancer agents to enhance therapeutic outcomes and overcome drug resistance.